Besides improving sensitivity and specificity of prostate cancer imaging, PSMA-targeted PET/CT has reduced the rate of equivocal findings compared to that seen with the previous standard procedures, CT and bone scan. This evidence concerns the gene FOLH1 and Familial prostate cancer.